In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia.
Gut bacteria-metabolized equol shows promise in cancer prevention
Researchers reviewed how soy isoflavones are metabolized by gut bacteria into equol, exploring its role in cancer prevention and treatment. They examined the molecular mechanisms
July 11, 2024